Hims & Hers Health Sees 2026 Adjusted EBITDA of $257 M to $277 M >HIMS

What happened

Hims & Hers Health said it expects 2026 adjusted EBITDA, a measure of operating earnings before interest, taxes, depreciation and amortization, to be between $257 million and $277 million. The supplied article provides no further details about the forecast.

Confirmed

Global impact / market context

The forecast gives investors a range for the company’s expected operating earnings in 2026. If achieved, stronger earnings could leave more cash available for business needs, while results below the range could limit that flexibility; the article does not explain the assumptions behind the estimate.

Analyst inference

The supplied context reports only the 2026 adjusted EBITDA range and gives no revenue forecast, spending plans, prior guidance, or market reaction. Investors therefore cannot assess from this report alone what sales, costs, or changes in the business underpin the expected earnings.

Analyst inference

What to watch

1. Look for the company to explain what revenue and cost assumptions support the $257 million to $277 million adjusted EBITDA range for 2026. Analyst inference
2. Watch for Hims & Hers to provide further detail on its 2026 adjusted EBITDA outlook, including how it expects its business performance to support the forecast range. Analyst inference
3. Compare any later reported 2026 adjusted EBITDA with the forecast range to assess whether the company is tracking toward, within, or below its stated outlook. Analyst inference

Evidence

• Original source link unavailable